China Diabetes Market Growth Report, Segments, Product Type, Application and Key Trends Forecast to 2023

1
    China Diabetes Market Propelled by
Improving Access to Treatment

Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
China Diabetes Market Propelled by Improving
Access to Treatment Over the past few years, the
China diabetes market has witnessed a positive
growth on account of a number of positive forces
which include augmenting demand for better
healthcare products and services, ageing
population and unhealthy lifestyle. According
to the latest report by IMARC Group, titled
China Diabetes Market Report 2018-2023,
the China diabetes market reached a value of more
than US 3 Billion in 2017, exhibiting a CAGR of
more than 15 during 2010-2017. Diabetes, also
known as diabetes mellitus, is a long-term health
condition which leads to an increase in the
levels of blood sugar. During this chronic
disease, the patients body does not produce
enough insulin to break down the sugar available
in food products. Currently, China has one of the
largest diabetic population in the world with
around 10 of the adult population living with
the disease owing to unhealthy changes in
lifestyles such as high level of smoking and
alcohol consumption, particularly among the rural
and middle-class population. Apart from this, the
prevalence of diabetes is higher at a relatively
young age and lower BMI level in China as
compared to the western population.
4
Report Description and Highlights
Report Description
Market Trends The healthcare reforms undertaken
by the Chinese government represent the major
factor which has driven the market growth.
Earlier, the healthcare system in the region
operated under a rudimentary socialist system
with little to no access to modern healthcare
services. However, the government has encouraged
foreign investments in recent years, allowing
multinational companies to offer their services
in the region. This has improved the access to
treatment, enabling the patients to identify
diabetes at earlier stages and manage it.
Additionally, as people over the age of 65 years
are at a higher risk of diabetes when compared to
the younger generations, the aging population has
further led to a growth in the demand for
diabetes management products. Moreover, rising
disposable incomes coupled with rapid
urbanization have led to a rise in the
consumption of junk food, lack of safe spaces to
exercise, sedentary lifestyles, etc., further
increasing the risk of diabetes. However, the
geographical disparity in China, in terms of
healthcare services provided to the eastern and
western provinces and the rural and urban
regions, hinders the growth of the China diabetes
market. Looking forward, the market is projected
to reach a value of nearly US 6 Billion by
2023. Read more here http//bit.ly/2DElcav
5
Report Description and Highlights
Report Description
  Want more information about
this market? Request a free report
sample https//www.imarcgroup.com/request?typere
portid556flagB
6
Report Description and Highlights

• Market Summary
• The diabetes market in China has been categorized
  into two main segments, namely, insulin and oral
  antidiabetics. Currently, the insulin segment
  holds the majority of the market share on account
  of a rise in the number of facilities established
  across the nation which produce and supply
  insulin pumps along with other insulin delivery
  systems.
• The competitive landscape of the market has also
  been examined with some of the key players being
  Sinocare, Roche, Abbott, Johnson Johnson,
  Bayer, and Beckman Coulter.
• Browse More Related Reports 
• Japan Diabetes Market http//bit.ly/2TqGlKu
• France Diabetes Market http//bit.ly/2PHF0Rl

7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us